Study of Adding AMG 479 to First Line Chemotherapy in Patients With Optimally Debulked Epithelial Ovarian Cancer
Status:
Terminated
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
This study will determine the value of adding AMG 479 (fully human monoclonal antibody
against IGF-1R) to paclitaxel and carboplatin first line chemotherapy in patients with
optimally debulked (<1 cm) FIGO stage III and IV (positive pleural cytology only) ovarian
epithelial (including fallopian tube and primary peritoneal) carcinoma.